Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia​

ZURICH (Reuters) - Novartis said on Wednesday a long term study of ‍its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally.